MedTrace Logo

Montelukast in Children With Wheezing

NCT00775697 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-06-19

No results posted yet for this study

Summary

In this study children with recurrent wheezing (\>/= 2 episodes in the last 6 months)and aged less than 2 years will be enrolled as outpatients. They will undergo lung function evaluation by Rint and by assessment of the flow curves at baseline and after 4 weeks of treatment with Montelukast 4 mg/day. Symptom dairies will be filled by parents during the study period.

Conditions

  • Wheezing

Interventions

DRUG

Montelukast

the arm will be treated with Montelukast 4 mg die for 4 weeks

DRUG

Montelukast

montelukast 4 mg day for 4 weeks

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Policlinico

    collaborator OTHER

  • Universita di Verona

    lead OTHER

Principal Investigators

  • Attilio L Boner, MD · Universita di Verona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775697 on ClinicalTrials.gov